Our understanding of TAAD pathophysiology and therapeutics in MFS has evolved since the original identification of a pathogenic losartan-responsive AT1r/TFGβ axis to the current more complex disease model requiring a multidrug strategy to slow down or even halt aneurysm progression. The gene discussed is AGTR1; the disease is aneurysm.